These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 32667699)

  • 1. Systematic review and meta-analysis of effectiveness of treatment options against SARS-CoV-2 infection.
    Thoguluva Chandrasekar V; Venkatesalu B; Patel HK; Spadaccini M; Manteuffel J; Ramesh M
    J Med Virol; 2021 Feb; 93(2):775-785. PubMed ID: 32667699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.
    Barlow A; Landolf KM; Barlow B; Yeung SYA; Heavner JJ; Claassen CW; Heavner MS
    Pharmacotherapy; 2020 May; 40(5):416-437. PubMed ID: 32259313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.].
    Cruciani F; Amato L; De Crescenzo F; Mitrova Z; Saulle R; Vecchi S; Davoli M
    Recenti Prog Med; 2021 Mar; 112(3):195-206. PubMed ID: 33687358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.
    Singh B; Ryan H; Kredo T; Chaplin M; Fletcher T
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013587. PubMed ID: 33624299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychopharmacology of COVID-19.
    Bilbul M; Paparone P; Kim AM; Mutalik S; Ernst CL
    Psychosomatics; 2020; 61(5):411-427. PubMed ID: 32425246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early experience with remdesivir in SARS-CoV-2 pneumonia.
    Durante-Mangoni E; Andini R; Bertolino L; Mele F; Florio LL; Murino P; Corcione A; Zampino R
    Infection; 2020 Oct; 48(5):779-782. PubMed ID: 32418190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials.
    Izcovich A; Siemieniuk RA; Bartoszko JJ; Ge L; Zeraatkar D; Kum E; Qasim A; Khamis AM; Rochwerg B; Agoritsas T; Chu DK; McLeod SL; Mustafa RA; Vandvik P; Brignardello-Petersen R
    BMJ Open; 2022 Mar; 12(3):e048502. PubMed ID: 35236729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pooled analysis of the MANTICO2 and MONET randomized controlled trials comparing drug efficacy for early treatment of COVID-19 during Omicron waves.
    Mazzotta V; Mazzaferri F; Lanini S; Mirandola M; Cozzi Lepri A; Vergori A; Savoldi A; Santoro A; Maccarrone G; Mastrorosa I; Simonetti O; Zottis F; Nicastri E; Rosini G; Rovigo L; Tavernaro L; Sarmati L; Tascini C; Girardi E; Cattelan AM; Antinori A; Tacconelli E;
    J Infect; 2024 Nov; 89(5):106294. PubMed ID: 39343244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19.
    Maciorowski D; Idrissi SZE; Gupta Y; Medernach BJ; Burns MB; Becker DP; Durvasula R; Kempaiah P
    SLAS Discov; 2020 Dec; 25(10):1108-1122. PubMed ID: 32942923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study.
    Garcia P; Revet A; Yrondi A; Rousseau V; Degboe Y; Montastruc F
    Drug Saf; 2020 Dec; 43(12):1315-1322. PubMed ID: 33078372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis.
    Wang M; Wu T; Zuo Z; You Y; Yang X; Pan L; Hu Y; Luo X; Jiang L; Xia Z; Deng M
    BMJ Support Palliat Care; 2021 Mar; 11(1):45-52. PubMed ID: 32958501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial.
    Reis G; Moreira Silva EADS; Medeiros Silva DC; Thabane L; Singh G; Park JJH; Forrest JI; Harari O; Quirino Dos Santos CV; Guimarães de Almeida APF; Figueiredo Neto AD; Savassi LCM; Milagres AC; Teixeira MM; Simplicio MIC; Ribeiro LB; Oliveira R; Mills EJ;
    JAMA Netw Open; 2021 Apr; 4(4):e216468. PubMed ID: 33885775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019.
    Kim JW; Kim EJ; Kwon HH; Jung CY; Kim KC; Choe JY; Hong HL
    Korean J Intern Med; 2021 Mar; 36(Suppl 1):S253-S263. PubMed ID: 32536150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended remdesivir administration in haematological patients with malignancies and COVID-19 during the Omicron era: safety and outcomes.
    Gras E; Aiello TF; Chumbita M; Gallardo-Pizarro A; Monzó-Gallo P; Teijón-Lumbreras C; Suárez-Lledó M; Magnano L; Tuset M; Marcos MÁ; Soriano A; Garcia-Vidal C
    J Antimicrob Chemother; 2024 Sep; 79(9):2364-2368. PubMed ID: 38985649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs.
    Vernaz N; Agoritsas T; Calmy A; Gayet-Ageron A; Gold G; Perrier A; Picard F; Prendki V; Reny JL; Samer C; Stirnemann J; Vetter P; Zanella MC; Zekry D; Baggio S
    Swiss Med Wkly; 2020 Dec; 150():w20446. PubMed ID: 33382449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports.
    Zekarias A; Watson S; Vidlin SH; Grundmark B
    Drug Saf; 2020 Dec; 43(12):1309-1314. PubMed ID: 32978702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of various treatment modalities for nCOV-2019: A systematic review and meta-analysis.
    Misra S; Nath M; Hadda V; Vibha D
    Eur J Clin Invest; 2020 Nov; 50(11):e13383. PubMed ID: 32810285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Hosseini FS; Malektojari A; Ghazizadeh S; Hassaniazad M; Davoodian P; Dadvand H; Nikpoor AR; Nikoofal-Sahlabadi S; Kahoori S; Sepandi M; Hassanipour S; Fathalipour M
    Trials; 2021 Jan; 22(1):4. PubMed ID: 33397429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
    Uzunova K; Filipova E; Pavlova V; Vekov T
    Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.